Wungki Park, MD, MS, is a gastrointestinal medical oncologist and physician-scientist at Memorial Sloan Kettering Cancer Center, specializing in pancreatic and biliary tract cancers. His clinical and translational research focuses on pancreatic cancer immunobiology, DNA damage repair, KRAS/RAS-directed therapeutics, therapeutic resistance and biomarker-driven precision oncology. Dr. Park led the POLAR trial of pembrolizumab plus olaparib maintenance therapy in metastatic pancreatic cancer, published in Nature Medicine, which integrated clinical outcomes with multidimensional translational analyses to better define immune contexture, DNA repair biology, and determinants of therapeutic sensitivity in pancreatic cancer. His broader contributions include individualized mRNA neoantigen vaccine studies in PDAC, clinicogenomic studies of KRAS mutant alleles and KRAS mutant dosage, and clinical development of novel KRAS-directed therapies including setidegrasib and daraxonrasib. Through his work, Dr. Park aims to connect human tumor biology with mechanism-guided clinical trial design and to develop more effective precision therapeutic strategies for patients with pancreatic and other gastrointestinal cancers.